Building on long-term data announced earlier this year, CVRx has reported durable improvements in heart failure patients with its Barostim device over 24 months. The results, published in the Journal ...

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...

Bringing a unique treatment for chronic heart failure to market has taken medical device startup CVRx two decades of effort and close to $400 million in financing. “To develop technology like this is, ...

CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...

Heavy selloff following top-line data from the BeAT-HF trial, that failed to meet primary endpoint. Still, there were numerous secondary data that were positive. CVRX is subsequently submitting for ...

CVRx's Barostim is a long-term compounder that presents with interesting economics. Clinical data is robust for the device and it continues to benefit from regulatory tailwinds. News around the device ...

The number of Americans living with congestive heart failure is on the rise; it’expected to affect more than eight million people by 2030. For many of those patients, medications stop working. Now a ...

After years of work, Minnesota-based device firm CVRx has obtained approval from the Food and Drug Administration to sell its neurostimulation device for heart failure commercially in the United ...

Minneapolis medical device maker CVRx Inc. is one step closer to putting to market what it says is the world’s first heart failure neuromodulation device. On Friday, the company announced that it has ...

CVRx Inc., the Brooklyn Park-based medical device maker, went public on Wednesday, raising $126 million. The shares were priced at $18 for the initial public offering. When they started trading late ...